Pharmacokinetics of levodopa and personalized therapy in Parkinson’s disease
A.A. TAPPAKHOV1,2, T.E. POPOVA2, T.G. GOVOROVA1, YU.I. KHABAROVA2, N.A.SHNAYDER3
1M.K. Ammosov North-Eastern Federal University, Institute of Medicine, Yakutsk
2Yakutsk Scientific Center for Complex Medical Problems, Yakutsk
3V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology,
St. Petersburg
Contact details:
Tappakhov A.A. — PhD (medicine), Associate Professor of the Department of Neurology and Psychiatry
Address: 27 Oyunsky St., Russian Federation, Yakutsk, 677016, tel.: +7 (4112) 49-67-65, e-mail: tappakhov@gmail.com
The article provides a review of the pharmacokinetics of levodopa and personalized therapy for Parkinson’s disease. We analyzed the methods used to prolong the action of levodopa using peripheral inhibitors of DOPA decarboxylase, catechol-O-methyltransferase inhibitors, and monoamine oxidase type B inhibitors. The influence of levodopa metabolites with their own biological activity in the possible progression of the disease is emphasized. The role of determining the concentration of levodopa in blood plasma is discussed, as well as the concept of «continuous dopamine stimulation» for the prevention and treatment of side effects of long-term levodopa therapy, such as drug dyskinesias, motor and non-motor fluctuations. The article also provides an overview of the modern forms of levodopa that are currently being investigated.
Key words: Parkinson’s disease, levodopa, dopamine, continuous dopamine stimulation, drug dyskinesias, motor fluctuations.
REFERENCES
- Berardelli A., Wenning G.K., Antonini A. et al. EFNS/MDS-ES recommendations for the diagnosis of Parkinson’s disease. Eur J Neurol, 2013, vol. 20, pp. 16–34. DOI:10.1111/ene.12022
- Illarioshkin S.N. Etiologiya bolezni Parkinsona: novye predstavleniya i novye vyzovy [Etiology of Parkinson’s Disease: New Ideas and New Challenges]. Bolezn’ Parkinsona i rasstroystva dvizheniy: rukovodstvo dlya vrachey po materialam III Natsional’nogo Kongressa. Moscow, 2014. Pp. 5–13.
- Heumann R., Moratalla R., Herrero M.T. et al. Dyskinesia in Parkinson’s disease: mechanisms and current non-pharmacological interventions. J Neurochem, 2014, vol. 130 (4), pp. 472–489. DOI:10.1111/jnc.12751
- Lim S-Y., Lang A.E. The nonmotor symptoms of Parkinson’s disease — an overview. Mov Disord, 2010, vol. 25 (1), pp. S123-130. DOI:10.1002/mds.22786
- Wright Willis A., Evanoff B., Lian M. et al. Geographic and ethnic variation in Parkinson disease: A population-based study of us medicare beneficiaries. Neuroepidemiology, 2010, vol. 34, pp. 143–151. DOI:10.1159/000275491
- Krivonos O.V. Organizatsiya meditsinskoy pomoshchi bol’nym bolezn’yu Parkinsona v sovremennykh sotsial’no-ekonomicheskikh usloviyakh [Organization of medical care for patients with Parkinson’s disease in modern socio-economic conditions]. Bolezn’ Parkinsona i rasstroystva dvizheniy: rukovodstvo dlya vrachey po materialam III Natsional’nogo Kongressa. Moscow, 2014. Pp. 217–220.
- Obeso J.A., Stamelou M., Goetz C.G. et al. Past, present, and future of Parkinson’s disease: A special essay on the 200th Anniversary of the Shaking Palsy. Mov Disord, 2017, vol. 32 (9), pp. 1264–1310. DOI:10.1002/mds.27115
- Politis M., Niccolini F. Serotonin in Parkinson’s disease. Behav Brain Res, 2015, vol. 277, pp. 136–145. DOI:10.1016/j.bbr.2014.07.037
- Zalyalova Z.A., Bagdanova N.I. Premotor stage of Parkinson’s disease: from hypotheses and theories to clinical practice. Nevrologicheskiy vestnik, 2018, no. 50 (3), pp. 63–68 (in Russ.).
- Levin O.S., Artem’ev D.V., Bril’ E.V. et al. Parkinson’s disease: modern approaches to diagnosis and treatment. Prakticheskaya meditsina, 2017, vol. 10, no. 102, pp. 45–51 (in Russ.).
- DeMaagd G., Philip A. Parkinson’s Disease and Its Management: Part 4: Treatment of Motor Complications. Pharmacy and therapeutics, 2015, vol. 40 (11), pp. 747–773.
- Clarke C.E. Does levodopa therapy delay death in Parkinson’s disease? A review of the evidence. Mov Disord, 1995, vol. 10 (3), pp. 250–256. DOI:10.1002/mds.870100303
- Morgan J.C., Currie L.J., Harrison M.B. et al. Mortality in levodopa-treated Parkinson’s disease. Parkinsons Dis, 2014, vol. 2014. DOI:10.1155/2014/426976
- Mytilineou C., Walker R.H., Jno Baptiste R. et al. Levodopa Is Toxic to Dopamine Neurons in an in Vitro but Not an in Vivo Model of Oxidative Stress. J Pharmacol Exp Ther., 2003, vol. 304 (2), pp. 792–800. DOI:10.1124/jpet.102.042267
- Titova N.V., Katunina E.A. Levodopa: the story continues. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova, 2014, no. 9, pp. 93–99 (in Russ.).
- Levin O.S. Levodopa-induced dyskinesias in Parkinson’s disease: possibilities of prevention and therapy. Sovremennaya terapiya v psikhiatrii i nevrologii, 2015, no. 3, pp. 15–25 (in Russ.).
- Zakharov D.V., Bogacheva V.A., Mikhaylov V.A. et al. Quality of life of patients with trembling form of Parkinson’s disease. Obozrenie psikhiatrii i meditsinskoy psikhologii, 2015, no. 1, pp. 33–37 (in Russ.).
- Encarnacion E.V., Hauser R.A. Levodopa-induced dyskinesias in Parkinson’s disease: Etiology, impact on quality of life, and treatments. Eur Neurol, 2008, vol. 60 (2), pp. 57–66. DOI:10.1159/000131893
- Nikitina M.A., Brazovskaya N.G., Zhukova N.G. et al. Apathy as a non-motor symptom of Parkinson’s disease and Huntington’s disease. Yakutskiy meditsinskiy zhurnal, 2020, no. 70 (2), pp. 24–27 (in Russ.).
- Akhmadeeva G.N., Magzhanov R.V., Tayupova G.N. et al. Clinical features, diagnosis and treatment of cognitive disorders in Parkinson’s disease. Nevrologiya, neyropsikhiatriya, psikhosomatika, 2017, no. 9 (1), pp. 101–105 (in Russ.). DOI:10.14412/2074-2711-2017-1-101-105
- Levin O.S. «Orchestra rehearsal»: neurotransmitter «polyphony» in Parkinson’s disease. Pozhiloy patsient, 2017, no. 1 (7), pp. 3–8 (in Russ.).
- Timpka J., Mundt-Petersen U., Odin P. Continuous dopaminergic stimulation therapy for Parkinson’s disease — Recent advances. Curr Opin Neurol, 2016, vol. 29 (4), pp. 474–479. DOI:10.1097/WCO.0000000000000354
- Müller T. Catechol-O-methyltransferase inhibitors in Parkinson’s disease. Drugs, 2015, vol. 75 (2), pp. 157–174. DOI:10.1007/s40265-014-0343-0
- Guthikonda L.N., Lyons K.E., Pahwa R. Continuous infusion of levodopa-carbidopa intestinal gel in Parkinson’s disease. J Comp Eff Res, 2014, vol. 3 (4), pp. 331–333. DOI:10.2217/cer.14.33
- Olanow C.W., Kieburtz K., Odin P.L.A. et al. Double-blind, double-dummy, randomized study of continuous intrajejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson’s disease. Lancet Neurol, 2014, vol. 13 (2), pp. 141–149. DOI:10.1016/j.ygyno.2014.12.035.Pharmacologic
- Fasano A., Bove F., Gabrielli M. et al. The role of small intestinal bacterial overgrowth in Parkinson’s disease. Mov Disord, 2013, vol. 28 (9), pp. 1241–1249. DOI:10.1002/mds.25522
- Levin O.S., Fedorova N.V. Bolezn’ Parkinsona [Parkinson’s disease]. Moscow: MEDPress-inform, 2014. 384 p.
- Riederer P., Gerlach M., Müller T. et al. Relating mode of action to clinical practice: dopaminergic agents in Parkinson’s disease. Parkinsonism Relat Disord, 2007, vol. 13 (8), pp. 466–479. DOI:10.1016/j.parkreldis.2007.06.015
- Guatteo E., Yee A., McKearney J. et al. Dual effects of l-DOPA on nigral dopaminergic neurons. Exp Neurol, 2013, vol. 247, pp. 582–594. DOI:10.1016/j.expneurol.2013.02.009
- Aureli C., Cassano T., Masci A. et al. 5-S-cysteinyldopamine neurotoxicity: Influence on the expression of α-synuclein and ERp57 in cellular and animal models of Parkinson’s disease. J Neurosci Res, 2014, vol. 92 (3), pp. 347–358. DOI:10.1002/jnr.23318
- Shiraishi T., Nishikawa N., Mukai Y. et al. High levodopa plasma concentration after oral administration predicts levodopa-induced dyskinesia in Parkinson’s disease. Park Relat Disord, 2020, vol. 75, pp. 80–84. DOI:10.1016/j.parkreldis.2020.05.022
- Elbarbry F., Nguyen V., Mirka A. et al. A new validated HPLC method for the determination of levodopa: Application to study the impact of ketogenic diet on the pharmacokinetics of levodopa in Parkinson’s participants. Biomed Chromatogr, 2019, vol. 33 (1), pp. 1–7. DOI:10.1002/bmc.4382
- Abaimov A.D., Sariev A.K., Pantyukhova E.Yu. et al. Sposob kolichestvennogo opredeleniya levodopy v plazme krovi [Method for the quantitative determination of levodopa in blood plasma]. Patent na izobretenie RU2665164 C1, 28.08.2018.Zayavka no. 2017142140 ot 4.12.2017.
- Nodel’ M.R. Levodopa: the search for standards for the «gold standard». Trudnyy patsient, 2009, no. 11 (7), pp. 33–38 (in Russ.).
- Stocchi F., Rascol O., Kieburtz K. et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE-PD study. Ann Neurol, 2010, vol. 68, pp. 18–27. DOI:10.1002/ana.22060
- Tambasco N., Romoli M., Calabresi P. Levodopa in Parkinson’s disease: Current Status and Future Developments. Curr Neuropharmacol, 2017, vol. 16 (8), pp. 1239–1252. DOI:10.2174/1570159×15666170510143821
- Ciesielska A., Samaranch L., San Sebastian W. et al. Depletion of AADC activity in caudate nucleus and putamen of Parkinson’s disease patients; Implications for ongoing AAV2-AADC gene therapy trial. PLoS One, 2017, vol. 12 (2), pp. 1–13. DOI:10.1371/journal.pone.0169965
- De Lau L.M.L., Verbaan D., Marinus J. et al. Catechol-O-methyltransferase Val158Met and the risk of dyskinesias in Parkinson’s disease. Mov Disord, 2012, vol. 27 (1), pp. 132–135. DOI:10.1002/mds.23805
- Muellner J., Gharrad I., Habert M.O. et al. Dopaminergic denervation severity depends on COMT Val158Met polymorphism in Parkinson’s disease. Parkinsonism Relat Disord, 2015, vol. 21 (5), pp. 471–476. DOI:10.1016/j.parkreldis.2015.02.009
- Brooks D.J., Sagar H. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson’s disease: A randomised, placebo controlled, double blind, six month study. J Neurol Neurosurg Psychiatry, 2003, vol. 74 (8), pp. 1071–1079. DOI:10.1136/jnnp.74.8.1071
- Almeida L., Rocha J.F., Falcão A. et al. Pharmacokinetics, Pharmacodynamics and Tolerability of Opicapone, a Novel Catechol-O-Methyltransferase Inhibitor, in Healthy Subjects. Clin Pharmacokinet, 2013, vol. 52 (2), pp. 139–151. DOI:10.1007/s40262-012-0024-7
- Ferreira J.J., Lees A., Rocha J.F. et al. Long-term efficacy of opicapone in fluctuating Parkinson’s disease patients: a pooled analysis of data from two phase 3 clinical trials and their open-label extensions. Eur J Neurol, 2019, vol. 26 (7), pp. 953–960. DOI:10.1111/ene.13914
- Müller T. Pharmacokinetics and pharmacodynamics of levodopa / carbidopa cotherapies for Parkinson’s disease. Expert Opin Drug Metab Toxicol, 2020, vol. 16 (5), pp. 403–414. DOI:10.1080/17425255.2020.1750596
- Müller T., Möhr J.D. Pharmacokinetics of monoamine oxidase B inhibitors in Parkinson’s disease: current status. Expert Opin Drug Metab Toxicol, 2019, vol. 15 (5), pp. 429–435. DOI:10.1080/17425255.2019.1607292
- Steventon G.B., Sturman S.G., Heafield M.T. et al. Platelet monoamine oxidase-B activity in Parkinson’s disease. J Neural Transm Park Dis Dement Sect, 1989, vol. 1 (4), pp. 255–261.
- Kumar M.J., Andersen J.K. Perspectives on MAO-B in aging and neurological disease: where do we go from here? Mol Neurobiol, 2004, vol. 30(1), pp. 77–89. DOI:10.1385/MN:30:1:077
- Balciuniene J., Emilsson L., Oreland L. et al. Investigation of the functional effect of monoamine oxidase polymorphisms in human brain. Hum Genet, 2002, vol. 110 (1), pp. 1–7. DOI:10.1007/s00439-001-0652-8
- Dézsi L., Vécsei L. Monoamine oxidase B inhibitors in Parkinson’s disease. CNS Neurol Disord Drug Targets, 2017.
- Cereda E., Cilia R., Canesi M. et al. Efficacy of rasagiline and selegiline in Parkinson’s disease: a head-to-head 3-year retrospective case–control study. J Neurol, 2017, vol. 264 (6), pp. 1254–1263. DOI:10.1007/s00415-017-8523-y
- Schapira A., Stocchi F., Borgohain R. et al. Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson’s disease. Eur J Neurol, 2013, vol. 20-(2), pp. 271–280. DOI:10.1111/j.1468-1331.2012.03840.x
- Freitas M.E., Ruiz-Lopez M., Fox S.H. Novel Levodopa Formulations for Parkinson’s Disease. CNS Drugs, 2016, vol. 30 (11), pp. 1079–1095. DOI:10.1007/s40263-016-0386-8
- Hauser R.A., Hsu A., Kell S. et al. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson’s disease and motor fluctuations: a phase 3 randomised, double-blind trial. Lancet Neurol, 2013, vol. 12 (4), pp. 346–356. DOI:10.1016/S1474-4422(13)70025-5
- Verhagen Metman L., Stover N., Chen C. et al. Gastroretentive carbidopa / levodopa, DM-1992, for the treatment of advanced Parkinson’s disease. Mov Disord, 2015, vol. 30 (9), pp. 1222–1228. DOI:10.1002/mds.26219
- Lewitt P.A., Ellenbogen A., Chen D. et al. Actively transported levodopa prodrug XP21279: a study in patients with Parkinson disease who experience motor fluctuations. Clin Neuropharmacol, 2012, vol. 35 (3), pp. 103–110. DOI:10.1097/WNF.0b013e31824e4d7d
- Nyholm D., Ehrnebo M., Lewander T. et al. Frequent administration of levodopa / carbidopa microtablets vs levodopa / carbidopa /entacapone in healthy volunteers. Acta Neurol Scand, 2013, vol. 127 (2), pp. 124–132. DOI:10.1111/j.1600-0404.2012.01700.x
- Lipp M.M., Batycky R., Moore J. et al. Preclinical and clinical assessment of inhaled levodopa for OFF episodes in Parkinson’s disease. Sci Transl Med, 2016, vol. 8 (360), pp. 360ra136. DOI:10.1126/scitranslmed.aad8858.